Advanced Laboratory CPT Codes
This document lists advanced laboratory CPT, HCPCS and related procedure codes that are referenced by the payer for reimbursement/policy purposes; it affects providers billing Blue Cross Blue Shield - Alabama for advanced laboratory testing.
No material clinical or coverage changes in this revision.
Coverage stance
Coverage stance
The document presents a code list only; it does not contain explicit coverage criteria, limitations, or clinical indications in the provided text.
Advanced laboratory CPT / HCPCS codes
| 0170U | Molecular pathology procedure, not otherwise classified (example) |
| 0171U | Molecular pathology procedure, not otherwise classified (example) |
| 0172U | Molecular pathology procedure, not otherwise classified (example) |
| 0173U | Molecular pathology procedure, not otherwise classified (example) |
| 0174U | Molecular pathology procedure, not otherwise classified (example) |
| 0175U | Molecular pathology procedure, not otherwise classified (example) |
| 0176U | Molecular pathology procedure, not otherwise classified (example) |
| 0177U | Molecular pathology procedure, not otherwise classified (example) |
| 0178U | Molecular pathology procedure, not otherwise classified (example) |
| 0179U | Molecular pathology procedure, not otherwise classified (example) |
| 0312U | Molecular pathology procedure, not otherwise classified (example) |
| 0313U | Molecular pathology procedure, not otherwise classified (example) |
| 0315U | Molecular pathology procedure, not otherwise classified (example) |
| 0317U | Molecular pathology procedure, not otherwise classified (example) |
| 0318U | Molecular pathology procedure, not otherwise classified (example) |
| 0319U | Molecular pathology procedure, not otherwise classified (example) |
| 0320U | Molecular pathology procedure, not otherwise classified (example) |
| 0322U | Molecular pathology procedure, not otherwise classified (example) |
| 0323U | Molecular pathology procedure, not otherwise classified (example) |
| 0324U | Molecular pathology procedure, not otherwise classified (example) |
| 81106 | Cystic fibrosis analysis; common mutation or targeted variant analysis (example) |
| 81107 | Cystic fibrosis analysis; extended mutation analysis (example) |
| 81109 | Cystic fibrosis full sequence analysis (example) |
| 81111 | Digestion, restriction fragment length polymorphism or other analysis (example) |
| 81120 | Oncology-related molecular analysis (example) |
| 81121 | Oncology-related molecular analysis (example) |
| 81162 | Molecular pathology procedure, tiered interpretation (example) |
| 81163 | Molecular pathology procedure, tiered interpretation (example) |
| 81164 | Molecular pathology procedure, tiered interpretation (example) |
| 81165 | Molecular pathology procedure, tiered interpretation (example) |
| 81200 | CFTR (cystic fibrosis) gene analysis (example) |
| 81201 | CFTR common variant analysis (example) |
| 81202 | Genetic testing, example gene (example) |
| 81203 | Genetic testing, example gene (example) |
| 81220 | Oncology genetic test (example) |
| 81341 | Genetic testing, example (example) |
| 81400 | Molecular pathology procedure, not otherwise specified (example) |
| 81401 | Molecular pathology procedure, not otherwise specified (example) |
| 81410 | Cancer susceptibility panel (example) |
| 81414 | Targeted genomic sequence analysis panel (example) |
| 81415 | Targeted genomic sequence analysis panel (example) |
| 81416 | Targeted genomic sequence analysis panel (example) |
| 81420 | Targeted genomic sequence analysis panel (example) |
| 81422 | Targeted genomic sequence analysis panel (example) |
| 81425 | Targeted genomic sequence analysis panel (example) |
| 81426 | Targeted genomic sequence analysis panel (example) |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.